| scholarly article | Q13442814 |
| P50 | author | Ron Shapiro | Q59747328 |
| Chethan Puttarajappa | Q84110359 | ||
| P2093 | author name string | Henkie P Tan | |
| P2860 | cites work | IVIG rescue therapy in renal transplantation | Q43552905 |
| Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause | Q43580802 | ||
| Detection of the complement degradation product C4d in renal allografts: diagnostic and therapeutic implications. | Q43830010 | ||
| Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection | Q44469234 | ||
| Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients | Q44584357 | ||
| Rituximab as treatment for refractory kidney transplant rejection | Q44899030 | ||
| Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection | Q45259438 | ||
| Impact of rituximab therapy for treatment of acute humoral rejection | Q45361905 | ||
| Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production | Q46270888 | ||
| C4d peritubular capillary staining in chronic allograft nephropathy and transplant glomerulopathy: an uncommon finding | Q46539083 | ||
| Transplant glomerulopathy may occur in the absence of donor-specific antibody and C4d staining | Q46945380 | ||
| Significance of the positive crossmatch test in kidney transplantation | Q47800073 | ||
| Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. | Q47862854 | ||
| Desensitization in HLA-incompatible kidney recipients and survival. | Q51018759 | ||
| HLA antibody identification with single antigen beads compared to conventional methods. | Q51303028 | ||
| The antiinflammatory activity of IgG: the intravenous IgG paradox | Q24676548 | ||
| Treatment options and strategies for antibody mediated rejection after renal transplantation | Q27021397 | ||
| The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection | Q28299356 | ||
| Introduction and overview of therapeutic apheresis | Q30451703 | ||
| Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries | Q31961631 | ||
| Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection | Q33382552 | ||
| Abrogation of anti-HLA antibodies via proteasome inhibition | Q33384617 | ||
| Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin | Q34362734 | ||
| Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment | Q34977911 | ||
| Complement C4d in graft capillaries -- the missing link in the recognition of humoral alloreactivity | Q35142594 | ||
| Antibody to human leukocyte antigen triggers endothelial exocytosis | Q35611613 | ||
| Implications of immunohistochemical detection of C4d along peritubular capillaries in late acute renal allograft rejection | Q36017741 | ||
| Antibody-mediated organ-allograft rejection | Q36263023 | ||
| Antibody-mediated renal allograft rejection: diagnosis and pathogenesis | Q36759900 | ||
| The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection | Q36772871 | ||
| Antibody mediated rejection: update 2006. | Q36910384 | ||
| Focal C4d+ in renal allografts is associated with the presence of donor-specific antibodies and decreased allograft survival | Q37315152 | ||
| The emerging issue of MICA antibodies: antibodies to MICA and other antigens of endothelial cells | Q37323152 | ||
| Strategies for human leukocyte antigen antibody detection | Q37554228 | ||
| The significance of C4d staining with minimal histologic abnormalities | Q37631388 | ||
| A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. | Q37756017 | ||
| The evolution and clinical impact of human leukocyte antigen technology | Q37780937 | ||
| Clinical and investigational use of proteasome inhibitors for transplant rejection | Q37931981 | ||
| The involvement of FcR mechanisms in antibody-mediated rejection | Q40042379 | ||
| Banff 07 classification of renal allograft pathology: updates and future directions | Q40121163 | ||
| C4d staining of renal allograft biopsies: a comparative analysis of different staining techniques | Q40260954 | ||
| An update on antibody reduction and rejection reversal following bortezomib use: a report of 52 cases across 10 centers | Q42731774 | ||
| Rescue therapy for early antibody mediated rejection with a proteasome inhibitor: a case report | Q43044457 | ||
| The fate of anti-HLA antibody among renal transplantation recipients treated with bortezomib | Q43044481 | ||
| Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates | Q43119566 | ||
| Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection | Q43166691 | ||
| Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies | Q43178469 | ||
| Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. | Q53659700 | ||
| Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. | Q54013696 | ||
| Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. | Q54469292 | ||
| Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation | Q54968980 | ||
| Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. | Q55034268 | ||
| The Relative Importance of Cytokine Gene Polymorphisms in the Development of Early and Late Acute Rejection and Six-Month Renal Allograft Pathology | Q59314392 | ||
| Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection | Q67773387 | ||
| Pathologic features of acute renal allograft rejection associated with donor-specific antibody, Analysis using the Banff grading schema | Q71157326 | ||
| Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries | Q73039869 | ||
| Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts | Q73338525 | ||
| Platelet-specific alloantigens in cadaveric renal transplantation. A prospective study. Effect of HPA-5b mismatch in acute vascular rejection of renal allografts | Q73648044 | ||
| Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection | Q74644326 | ||
| Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial | Q79364646 | ||
| Successful rescue of refractory, severe antibody mediated rejection with splenectomy | Q79552624 | ||
| Distribution of donor-specific antibodies in the cortex and the medulla of renal transplants with chronic allograft nephropathy | Q79854817 | ||
| Analysis of renal transplant protocol biopsies in ABO-incompatible kidney transplantation | Q79897615 | ||
| C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings | Q80061434 | ||
| Rituximab therapy for acute humoral rejection after kidney transplantation | Q80318231 | ||
| Donor kidney exchanges | Q80563244 | ||
| In vivo platelet-endothelial cell interactions in response to major histocompatibility complex alloantibody | Q80763569 | ||
| Antibodies against MICA antigens and kidney-transplant rejection | Q81357717 | ||
| Vimentin antibodies: a non-HLA antibody as a potential risk factor in renal transplantation | Q81680338 | ||
| C1q-Fixing Human Leukocyte Antigen Antibodies Are Specific for Predicting Transplant Glomerulopathy and Late Graft Failure After Kidney Transplantation | Q82659907 | ||
| The fate of C4d positive kidney allografts lacking histological signs of acute rejection | Q82897466 | ||
| Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA) | Q83101436 | ||
| Transplant glomerulopathy: morphology, associations and mechanism | Q84203169 | ||
| Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection | Q84261290 | ||
| Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients | Q84977614 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | antibody | Q79460 |
| kidney transplantation | Q740909 | ||
| P304 | page(s) | 193724 | |
| P577 | publication date | 2012-04-10 | |
| P1433 | published in | Journal of transplantation | Q26842064 |
| P1476 | title | Antibody-mediated rejection in kidney transplantation: a review | |
| P478 | volume | 2012 |
| Q39105369 | Acute antibody-mediated rejection in kidney transplant recipients |
| Q33601185 | Alloprimed CD8(+) T cells regulate alloantibody and eliminate alloprimed B cells through perforin- and FasL-dependent mechanisms |
| Q52401610 | Antibody-mediated rejection: New approaches in prevention and management. |
| Q39018530 | Bortezomib in the treatment of antibody-mediated rejection in pediatric kidney transplant recipients: A multicenter Midwest Pediatric Nephrology Consortium study |
| Q37682802 | Budget impact of switching from an immediate-release to a prolonged-release formulation of tacrolimus in renal transplant recipients in the UK based on differences in adherence. |
| Q35846718 | Characterization of N-glycosylation and amino acid sequence features of immunoglobulins from swine |
| Q38079301 | Clinical relevance of antibody development in renal transplantation |
| Q88663316 | Contemporary Strategies and Barriers to Transplantation Tolerance |
| Q34392504 | Critical role of NKT cells in posttransplant alloantibody production. |
| Q34841849 | Diagnosis and management of antibody-mediated rejection: current status and novel approaches |
| Q58733582 | Donor-derived Cell-free DNA Identifies Antibody-mediated Rejection in Donor Specific Antibody Positive Kidney Transplant Recipients |
| Q39842547 | Donor-specific HLA antibodies and graft function in kidney-transplanted children - the Vienna cohort |
| Q51320634 | Effect of infusion of monoclonal antibodies to tumour necrosis factor-receptor super family 25 on graft rejection in allo-immune mice receiving autologous marrow transplantation. |
| Q40571069 | Evaluation of Renal Allograft Biopsies for Graft Dysfunction and Relevance of C4d Staining in Antibody Mediated Rejection |
| Q28069956 | Genetic barriers in transplantation medicine |
| Q52656958 | Human Cytomegalovirus Infection Increases Both Antibody- and Non-Antibody-Dependent Cellular Reactivity by Natural Killer Cells. |
| Q34587940 | IL2-IL21 gene cluster polymorphism is not associated with allograft function after kidney transplantation. |
| Q47130649 | Impact of Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibody C1q-Binding Ability on Kidney Allograft Outcome. |
| Q49297064 | Impact of complement component 3/4/5 single nucleotide polymorphisms on renal transplant recipients with antibody-mediated rejection |
| Q89594061 | Inverse Association Between the Quantity of Human Peripheral Blood CXCR5+IFN-γ+CD8+T cells with De Novo DSA Production in the First Year After Kidney Transplant |
| Q52310243 | Kidney Transplantation: The Challenge of Human Leukocyte Antigen and Its Therapeutic Strategies. |
| Q47778948 | Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation. |
| Q47100818 | Novel Non-Histocompatibility Antigen Mismatched Variants Improve the Ability to Predict Antibody-Mediated Rejection Risk in Kidney Transplant |
| Q43779103 | Pretransplant risk stratification for early survival of renal allograft recipients. |
| Q47680604 | Prevention of chronic renal allograft rejection by AS2553627, a novel JAK inhibitor, in a rat transplantation model |
| Q35007419 | Quantifying renal allograft loss following early antibody-mediated rejection. |
| Q35644308 | Renal graft biopsy assists diagnosis and treatment of renal allograft dysfunction after kidney transplantation: a report of 106 cases |
| Q92894871 | Renal resistive index as a predictive factor of delayed graft function: A meta-analysis |
| Q37241071 | Rituximab in the treatment of refractory late acute antibody-mediated rejection: Our initial experience |
| Q35925753 | Roles of mycobacterium tuberculosis ESAT-6 in the development of renal injury |
| Q91028577 | Sox7 is involved in antibody-dependent endothelial cell activation and renal allograft injury via the Jagged1-Notch1 pathway |
| Q37200645 | Successful Salvage Treatment of Resistant Acute Antibody-Mediated Kidney Transplant Rejection with Eculizumab |
| Q40958100 | Successful treatment of severe acute antibody-mediated rejection of renal allografts with bortezomib--a report of two pediatric cases |
| Q39075932 | The Impact of HLA Class I-Specific Killer Cell Immunoglobulin-Like Receptors on Antibody-Dependent Natural Killer Cell-Mediated Cytotoxicity and Organ Allograft Rejection |
| Q39254100 | The effect of histopathologic and clinical features on allograft survival in renal transplant patients with antibody-mediated rejection |
| Q27021227 | The importance of C4d in biopsies of kidney transplant recipients |
| Q38118112 | Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013. |
| Q26778752 | Translational research in kidney transplantation and the role of patient engagement |
| Q39093942 | Transplantation tolerance: don't forget about the B cells |
| Q35148001 | Two-stage, in silico deconvolution of the lymphocyte compartment of the peripheral whole blood transcriptome in the context of acute kidney allograft rejection |
| Q44266817 | Use of the ImmuKnow assay to evaluate the effect of alemtuzumab-depleting induction therapy on cell-mediated immune function after renal transplantation |
| Q39642946 | mTOR Inhibition Suppresses Posttransplant Alloantibody Production Through Direct Inhibition of Alloprimed B Cells and Sparing of CD8+ Antibody-Suppressing T cells. |
Search more.